This inventor holds 2 USPTO granted patents. Top assignees: Cedona Pharmaceuticals B.v., Seed Capital Investment (Sci) B.v.. Active years: 1993-1998.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1993-1998
Title: Henderikus Van Der Goot: Innovator in Pharmaceutical Chemistry
Introduction
Henderikus Van Der Goot is a notable inventor based in Hoofddorp, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on imidazole-derivatives. With a total of 2 patents to his name, Van Der Goot has established himself as a key figure in the development of compounds with therapeutic potential.
Latest Patents
His latest patents focus on imidazole-derivatives that exhibit agonistic or antagonistic activity on the histamine H3 receptor. The invention specifically relates to derivatives characterized by a general formula that includes isothiourea, guanidine, and amidine derivatives. These novel compounds are not only significant for their pharmacological properties but also for their potential applications in pharmaceutical compositions aimed at treating various conditions related to histamine receptors.
Career Highlights
Throughout his career, Henderikus Van Der Goot has worked with several prominent companies, including Seed Capital Investment B.V. and Cedona Pharmaceuticals B.V. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research and development.
Collaborations
Some of his notable coworkers include Hendrik Timmerman and John C. Eriks. Their collaborative efforts have further advanced the research and application of the compounds developed by Van Der Goot.
Conclusion
Henderikus Van Der Goot's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his importance in the field. His work continues to influence the development of new therapeutic agents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile